Black Starlight Capital is a research-driven investment operation focused on identifying asymmetric opportunities in the biotech and specialty finance sectors before the market prices them in. We operate at the intersection of quantitative signal processing and fundamental analysis — building proprietary frameworks that surface acquisition targets, rate-sensitive dislocations, and structural mispricings before they become consensus trades.

Our approach is systematic but not mechanical. Every model output is a starting point for deeper diligence, not a conclusion. We believe the edge in modern markets is not access to information — it is the ability to structure that information into a coherent, repeatable investment thesis faster and more rigorously than others.

The M&A Intelligence system scores a 500+ stock biotech universe daily across six proprietary layers — strategic value, acquirability, financial health, catalyst signals, acquisition pattern matching, and institutional research alignment. Conviction tiers are gated by mandatory clinical and commercial thresholds, not score alone. Picks are tracked from first identification, with staleness penalties applied over time to ensure signal quality does not decay.

The mREIT Scanner monitors the spread between net asset value and market price in mortgage REITs, cross-referenced against Fed policy trajectory, duration exposure, and insider positioning — isolating situations where rate expectations and book value diverge in ways the market has not yet corrected.

We do not trade noise. We do not chase momentum. We build positions in situations where the structural setup — pipeline readout windows, patent cliff pressure on acquirers, book value dislocations — creates a defined catalyst path within a visible time horizon. Discipline over activity. Precision over volume.